CD19 and B-cell non-Hodgkin lymphoma: Results of trial NCT03258047 have been published recently.33 34 In this trial, the PD1:CD28 receptor containing the AA141 cysteine has been tested in anti-CD19 CAR-engineered T cells for treatment of PD-L1-positive B cell lymphoma.